Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if Niraparib can help to control
metastatic pancreatic cancer. The safety of this drug will also be studied. Niraparib is FDA
approved and commercially available for the treatment of ovarian cancer. Its use in this
study is investigational.